Review: Diagnosis and management of non-cystic fibrosis bronchiectasis.
Diagnosis and management of non-cystic fibrosis bronchiectasis – Clinical Medicine Journal
The post Review: Diagnosis and management of non-cystic fibrosis bronchiectasis. appeared first on Links Medicus.
Review: Lung cancer for the non-respiratory physician.
Lung cancer for the non-respiratory physician – Clinical Medicine Journal
The post Review: Lung cancer for the non-respiratory physician. appeared first on Links Medicus.
Interstitial lung disease on the acute take for the non-respiratory physician.
Interstitial lung disease on the acute take for the non-respiratory physician – Clinical Medicine Journal
The post Interstitial lung disease on the acute take for the non-respiratory physician. appeared first on Links Medicus.
Modern day management of a unilateral pleural effusion.
Modern day management of a unilateral pleural effusion – Clinical Medicine Journal
The post Modern day management of a unilateral pleural effusion. appeared first on Links Medicus.
Update in the diagnosis and management of acute pulmonary embolism for the non-respiratory physician.
Update in the diagnosis and management of acute pulmonary embolism for the non-respiratory physician – Clinical Medicine Journal
The post Update in the diagnosis and management of acute pulmonary embolism for the non-respiratory physician. appeared first on Links Medicus.
New Zealand to ban smoking for next generation in bid to outlaw habit by 2025 – “New legislation means the legal smoking age will increase every year, to create a smoke-free generation of New Zealanders”.
New Zealand to ban smoking for next generation in bid to outlaw habit by 2025 – The Guardian
The post New Zealand to ban smoking for next generation in bid to outlaw habit by 2025 – “New legislation means the legal smoking age will increase every year, to create a smoke-free generation of New Zealanders”. appeared first on Links Medicus.
RCT: Among children between the ages of 6 and 11 years with uncontrolled moderate-to-severe asthma, add-on Dupilumab reduced exacerbations and improved lung function.
Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma – New England Journal of Medicine Commentary: International study supports dupilumab for treatment of moderate-to-severe asthma in children – Vanderbilt University Medical Center
The post RCT: Among children between the ages of 6 and 11 years with uncontrolled moderate-to-severe asthma, add-on Dupilumab reduced exacerbations and improved lung function. appeared first on Links Medicus.
Multiple early studies find notable Omicron vaccine evasion.
Multiple early studies find notable Omicron vaccine evasion – CIDRAP Related: A first, small study suggests Omicron is a larger threat to Covid-19 immunity than other variants.
The post Multiple early studies find notable Omicron vaccine evasion. appeared first on Links Medicus.
As 57 countries report Omicron cases, Pfizer says its boosters offer protection – but WHO cautions more research is needed.
As 57 Countries Report Omicron Cases, Pfizer Says its Boosters Offer Protection – But WHO Cautions More Research is Needed – Health Policy Watch See also: Covid: Vaccines should work against Omicron variant, WHO says – BBC
The post As 57 countries report Omicron cases, Pfizer says its boosters offer protection – but WHO cautions more research is needed. appeared first on Links Medicus.
[Press release – not published yet] Lab study suggests a third dose (booster) of the Pfizer–BioNTech vaccine may be necessary to provide an adequate immune response to the Omicron variant.
Press release: Pfizer and Biontech provide update on Omicron variant Commentaries: Omicron likely to weaken COVID vaccine protection – Nature Pfizer-BioNTech says COVID booster should protect against Omicron – CIDRAP Expert reaction to press release from Pfizer-BioNTech about omicron and neutralising antibody titres after two and three vaccine doses – Science Media Centre Covid: Pfizer […]
The post [Press release – not published yet] Lab study suggests a third dose (booster) of the Pfizer–BioNTech vaccine may be necessary to provide an adequate immune response to the Omicron variant. appeared first on Links Medicus.